ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 6 of 49
УЖМБС 2019, 4(4): 38–44
Experimental Medicine and Morphology

Simvastatin and Recombinant Antagonist of Receptors of Interleukin-1 Modulate Aryl Hydrocarbon Receptors in Experimental Colitis in Rats

Zherebiatiev A. S., Voitovich A. V.

The pathogenesis of inflammatory bowel disease is complex and multifactorial. Studies have led to the current concept that aryl hydrocarbon receptors have recently emerged as a critical physiological regulator of immune responses affecting both innate and adaptive systems. We studied the possibility of simvastatin and antagonist of receptors of interleukin-1 for pharmacological correction of colitis in rats with a focus on the expression intensity studies of AhR with lymphocytes of colon. Eight-month-old male Wistar rats (body mass 260-285 g) were purchased from Institution of Molecular Biology and Genetics (National Academy of Science of Ukraine, Kyiv) and kept in a 12-h light/dark cycle with controlled humidity (60–80%) and temperature (22°±1°C). Food and water were freely available. All animal experiments were performed according to international principles "of the European Convention for the Protection of vertebrate animals used for experimental and other scientific purposes" (Strasbourg, 18.03.1986) and "General ethical principles of animal research" (Ukraine, 2001). Rats were divided into four experimental groups: group 1 – control; group 2 – rats with oxazolone-induced colitis; group 3 – rats given simvastatin (20 mg/kg, for 5 days, intraperitoneally) ; group 4 – rats given antagonist of receptors of interleukin-1 (3 mg/kg, for 5 days, subcutaneously). Formalin-fixed, paraffin embedded colon sections (5-7 μm) placed on coated slides were sequentially deparaffinized and rehydrated using xylene and ethanol, washed in PBS (twice, 5 min each). The aryl hydrocarbon receptor immunopositive lymphocytes were determined using an indirect immunofluorescence technique with using a monoclonal rat antibody. After rinsing in 0.1 M PBS, the sections were incubated overnight at 4°C with the respective primary antibody: Aryl hydrocarbon Receptor. On the second day, after washing, sections were incubated for 1 h with a mixture of FITC-conjugated goat anti-rabbit IgG. Fluorescent images were obtained with a fluorescence microscope PrimoStar with a computer-assisted video system AxioCam 5c. The histological observation showed inflammatory cell infiltration, including polymorphonuclear leukocytes and multiple erosive lesions in the large intestine. Occasionally, crypt abscess and regenerated epithelium were seen in the colonic mucosa. We established that development of colitis was not accompanied with the change of amount of AhR+ lymphocytes. Drug administration during the development of experimental pathology was accompanied by changes in the expression of AhR on lymphocytes. Simvastatin and antagonist of receptors of interleukin-1 seemed to be beneficial in oxazolone -induced colitis rat model through modulate aryl hydrocarbon receptor expression with lymphocytes of colon.

Keywords: colitis, recombinant antagonist of receptors of interleukin-1 (ARIL-1), simvastatin, aryl hydrocarbon receptor

Full text: PDF (Ua) 300K

  1. Bereswill S, Munoz M, Fischer A, Plickert R, Haag LM, Otto B, et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One. 2010; 5(12): 21-8.
  2. Furumatsu K, Nishiumi S, Kawano Y, Ooi M, Yoshie T, Shiomi Y, et al. A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig Dis Sci. 2011; 56(9): 2532-44.
  3. Greenwood J, Steinman L, Zamvil S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006; 6(5): 358-70.
  4. Ho P, Steinman L. The aryl hydrocarbon receptor: a regulator of Th17 and Treg cell development in disease. Cell Res. 2008; 18(6): 605-8.
  5. Ishizuka K, Sugimura K, Homma T, Matsuzawa J, Mochizuki T, Kobayashi M, et al. Influence of interleukin-10 on the interleukin-1 receptor antagonist/interleukin-1 beta ratio in the colonic mucosa of ulcerative colitis. Digestion. 2001; 63 Suppl 1: 22-7.
  6. Jahovic N, Gedik N, Ercan F, Sirvanci S, Yüksel M, Sener G, et al. Effects of statins on experimental colitis in normocholesterolemic rats. Scand J Gastroenterol. 2006; 41(8): 954-62.
  7. Kaser A, Zeissig S, Blumberg R. Inflammatory bowel disease. Annu Rev Immunol. 2010; 28: 573-621.
  8. Kojima R, Kuroda S, Ohkishi T, Nakamaru K, Hatakeyama S. Oxazolone-induced colitis in BALB/C mice: a new method to evaluate the efficacy of therapeutic agents for ulcerative colitis. J Pharmacol Sci. 2004; 96(3): 307-13.
  9. Lee J, Kim J, Kim J, Kim N, Jung HC, Song IS. Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol. 2007; 7(2): 241-8.
  10. Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Dinarello CA, et al. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol. 2004; 138(2): 323-9.
  11. Maeda S, Ohno K, Nakamura K, Uchida K, Nakashima K, Fukushima K, et al. Mucosal imbalance of interleukin-1β and interleukin-1 receptor antagonist in canine inflammatory bowel disease. Vet J. 2012; 194(1): 66-70.
  12. Maher B, Dhonnchu T, Burke J, Soo A, Wood AE, Watson RW. Statins alter neutrophil migration by modulating cellular Rho activity a potential mechanism for statins-mediated pleotropic effects? J Leukoc Biol. 2009; 85(1): 186-93.
  13. Monteleone I, MacDonald T, Pallone F, Monteleone G. The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis. Curr Opin Gastroenterol. 2012; 28(4): 310-3.
  14. Sciullo E, Vogel C, Li W, Matsumura F. Initial and extended inflammatory messages of the nongenomic signaling pathway of the TCDD-activated Ah receptor in U937 macrophages. Arch Biochem Biophys. 2008; 480(2): 143-55.
  15. Stockinger B, Veldhoen M, Hirota K. Modulation of Th17 development and function by activation of the aryl hydrocarbon receptor--the role of endogenous ligands. Eur J Immunol. 2009; 39(3): 652-4.
  16. Tountas N, Casini-Raggi V, Yang H, Di Giovine FS, Vecchi M, Kam L, et al. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology. 1999 Oct; 117(4): 806-13.
  17. Veldhoen M, Hirota K, Westendorf A, Buer J, Dumoutier L, Renauld JC, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008; 453(7191): 106-9.
  18. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007; 2(3): 541-6.
  19. Youngman K, Simon P, West G, Cominelli F, Rachmilewitz D, Klein JS, et al. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology. 1993; 104(3): 749-58.